Yeast α-Glucosidase Inhibitory Activity of Some Antidiabetic Plants from the Philippines (original) (raw)
Related papers
Journal of Herbmed Pharmacology
Introduction: α-Glucosidase is the major enzyme implicated in intestinal glucose absorption, and its inhibition is a target for the management of diabetes mellitus. This study investigated the in vitro α-glucosidase inhibitory activity of extracts from different parts of 20 selected medicinal plants and the potential for plant-part substitution and plant species combinations used by traditional healers to treat diabetes. Methods: Acetone and petroleum ether extracts from different parts of 20 plant species traditionally used to treat diabetes were individually evaluated in vitro using an α-glucosidase assay. The potential for plant-part substitution was investigated by including leaf extracts where non-renewable parts are used traditionally. The extracts of plant species were combined and investigated as used traditionally. Results: Anthocleista grandiflora stem bark acetone, Artabotrys brachypetalus leaf petroleum ether, and Dichrostachys cinerea root petroleum ether extracts exhib...
Journal of Developing Drugs, 2015
Inhibition of α-glucosiase and the associated reduction of glucose absorption is an attractive approach for decreasing postprandial hyperglycemia and for the discovery of potent antidiabetic agents. One of the most important sources of potential α-glucosiase inhibitors represents the class of polyphenols. This paper aims to evaluate previous herbal polyphenol-rich extracts plan on the management of diabetes mellitus, to address their α-glucosidase inhibitory activity. Polyphenol-rich extracts from thirteen widely used traditionally anti-diabetic plants in Asia and Mediterranean regions were evaluated for their potential α-glucosidase inhibitory activity. Among these evaluated plants, 10 were much stronger than that of acarbose standard. Punica granatum manifested the highest inhibitory activity with IC 50 at 3.59 ± 0.11 µg/mL, followed by Psidium guajava with IC 50 at 8.08 ± 0.10 µg/mL and Cinnamomum zeylanicum with IC 50 at 9.87.08 ± 0.14 µg/mLA. A high correlation (r=0.65, p<0.001) was observed between α-glucosidase inhibition and total phenolic content of all plants. Punica granatum, P. guajava, C. zeylanicum and Ziziphus spina-christi had also the highest total phenolic content. Extracts for the above studied plant species may potentially replace acarbose in its current clinical use in improving post-prandial glycaemic control in type 2 diabetics. As a result, these polyphenol-rich extracts potentially offer a complementary approach to develop functional food and potential antidiabetic agents.
Glucosidase inhibitory potential of selected anti-diabetic plants used in North-Western Nigeria
Journal of Medicinal Plants Research, 2013
α-Glucosidase inhibitory potential of selected anti-diabetic plants has been studied. The study evaluated α-glucosidase inhibition using α-glucosidase from Saccharomyces cerevisiae and pnitrophenyl α-D-glucopyranoside as substrate. The result showed that the extract of Albizzia chevalieri leaf, Khaya senegalensis stem bark, Zizypus spina-christi stem bark, Arachis hypogea seed varieties and Mangifera indica leaf had significant (P < 0.05) α-glucosidase inhibitory effect in a concentration dependant manner as compared to acarbose. Cardiac glycosides, alkaloids, saponins, flavonoids and tannins were identified in the extracts. The study concludes that the plant extract contain bioactive compound that may be source(s) of lead compounds with α-glucosidase inhibitory potentials and may explain their hypoglycaemic effects.
Alpha Glucosidase Inhibitory Activity of Selected Philippine Plants
Abstract Ethnopharmacological relevance: Antidesma bunius Spreng. (Phyllantaceae), Averrhoa bilimbi (Oxalidaceae), Biophytum sensitivum DC. (Oxalidaceae), Ceriops tagal (Perr.) C.B.Rob. (Rhizophoraceae), Kyllinga monocephala Rottb. (Cyperaceae), and Rhizophora mucronata Lam. (Rhizophoraceae) are used as remedies to control diabetes. Aim of the study: To screen the six plants for their potential α-glucosidase inhibitory activity Materials and Methods: The 80% aqueous ethanolic extracts were screened for their α-glucosidase enzyme inhibitory activity using yeast alpha glucosidase enzyme. Results: Except for A. bilimbi with IC50 value of 519.86±3.07, all manifested a significant enzyme inhibitory activity. R. mucronata manifested the highest activity with IC50 0.08±1.82 μgmL-1, followed by C. tagal IC50 0.85±1.46 μgmL-1 and B. sensitivum IC50 at 2.24±1.58 μgmL-1. Conclusion: This is the first report on the α-glucosidase inhibitory effect of the six Philippine plants; thus, partly defining the mechanism on why these medicinal plants possess antidiabetic properties. Keywords: α-Glucosidase; Antidesma bunius; Averrhoa bilimbi; Biophytum sensitivum; Ceriops tagal; Kyllinga monocephala; Rhizophora mucronata; Diabetes
α-Glucosidase inhibitory activity of selected Philippine plants
Journal of Ethnopharmacology, 2012
a b s t r a c t Ethnopharmacological relevance: Antidesma bunius Spreng. (Phyllantaceae), Averrhoa bilimbi L. (Oxalidaceae), Biophytum sensitivum (L.) DC. (Oxalidaceae), Ceriops tagal (Perr.) C.B. Rob. (Rhizophoraceae), Kyllinga monocephala Rottb. (Cyperaceae), and Rhizophora mucronata Lam.
Asian Journal of Pharmaceutical and Clinical Research
Objective: Diabetes mellitus is a highly prevalent chronic disease in Egypt leading to high socioeconomic problems, especially in the cities due to the unhealthy life style. Although many drugs are available, they have many side effects. Furthermore, the body arouses resistance after a while for the drug so it should be changed every once in a while. Plants could be a good source for drugs. In Egypt, we have a rich flora which has not been subjected to systematic screening for antidiabetic activity.Methods: The aim of this work was to screen 264 plant extracts for their in vitro α-glucosidase inhibitory activity. Those extracts which gave more than 70% inhibition were screened on different concentrations and their inhibitory concentrations giving 50% activity (IC50) were calculated.Results: Out of all the tested extracts, 63 gave more than or equal 70% inhibition on α-glucosidase at the tested concentration (25 ppm). After the calculation of the IC50 values, 10 extracts were chosen ...
EVALUATION OF SELECTED MEDICINAL HERBS FOR ANTIDIABETIC ACTIVITY VIA ALPHA-GLUCOSIDASE INHIBITION
Literature and native therapies have cited bitter melon, dandelion, blueberry, and roselle, as hypoglycemic agents, however, the exact mechanisms of action are unknown. It was hypothesized that, these agents could induce hypoglycemia, through the mechanism of α-glucosidase inhibition. The aim of the present study was, to examine inhibition of alpha-glucosidase as one of the possible mechanisms of action, of bitter melon (Mormodicacharantia), dandelion (Taraxacumofficinale), blueberry (Vacciniumcorybosum), and roselle (Hibiscus sabdariffa). Each of these agents has been used in the treatment of diabetes in, different parts of the world. The study was done in vitro, using α-glucosidase, obtained from Bacillus. The inhibitory effect of different concentrations of alcoholic extracts of the plants, on α-glucosidase was studied. The extracts of the plant showed inhibitory activities, against α-glucosidase, with IC50 values in a dose dependent manner. The result demonstrated that, bitter melon, roselle, dandelion, and blueberry share similar mechanism of action with Acarbose, which is being used as an antidiabetic agent.
2019
Plants constitute a major ingredient in traditional or folk medicine. The therapeutic claims made on the use of these traditional medicinal plants range from simple conditions such as fevers and migraines, to more complex diseases such as cancer, metabolic syndrome and diabetes mellitus. The aqueous ethanolic extracts of five medicinal plant species; Cosmos caudatus, Leucaena leucocephala, Momordica charantia, Pereskia bleo and Averrhoa bilimbi were assessed for glucose lowering effect via the in vitro α-glucosidase inhibition assay. Their antioxidant potential, represented by their DPPH radical scavenging activity and total phenolic contents were also measured. The most potent α-glucosidase inhibitory activity was recorded for the leaf extract of C. caudatus with IC50 of 21.90 ± 3.60 µg/mL, followed by L. leucocephala with IC50 value of 30.80 ± 2.50 µg/mL. Momordica charantia, P. bleo and A. bilimbi did not show any significant inhibition of α-glucosidase. Meanwhile C. caudatus als...
Journal of Babol University of Medical Sciences, 2023
Background and Objective: Control of hyperglycemia after meals is an important strategy in the management of type II diabetes, and the reduction of chronic complications associated with it. Therefore, inhibitors of carbohydrate-degrading enzymes such as α-glucosidase can be useful in the treatment of this disease. The aim of this study was to evaluate the α-glucosidase inhibitory activity in some traditional medicines in Sulaymaniyah province of Iraq. Methods: Eight plant species were prepared with advisory from authentic spiceries in Sulaymaniyah. After air drying and preparation of their methanolic extracts, enzyme microplate assay was conducted on them in four different extract concentrations (1, 0.1, 0.01 and 0.001 mg/ml) along with negative and positive controls. Finally, enzyme kinetic analysis was performed on effective extracts. Findings: Among the eleven studied plant species, Rubus idaeus L., Rheum ribes R. and Salix alba L. extracts at 1 mg/mL concentration showed highest inhibitory activity (98.13±1.05% (IC50=0.046 mg/mL), 93.39±2.11% (IC50=0.085 mg/mL) and 84.46±1.12% (IC50=0.125 mg/mL), respectively) against α-glucosidase,. After kinetic analysis of α-glucosidase inhibition, Rubus idaeus L., Rheum ribes R. extracts showed mixed type of inhibition (competitive- uncompetitive) while extract of Salix alba showed uncompetitive type of inhibition. Conclusion: The leave extract from both Rubus idaeus, Salix alba and root extract of Rheum ribes are remarkable α-glucosidase inhibitors, and may be used in the treatment of type II diabetics after clinical tests.